Blueberry Improves the Therapeutic Effect of Etanercept on Patients with Juvenile Idiopathic Arthritis: Phase III Study
Zhong Y, Wang Y, Guo J, Chu H, Gao Y, Pang L
The Tohoku journal of experimental medicine · 15 citas
Etiquetas de revisión
Alimentación controladaFinanciación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- Comida provista por los investigadores
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2015-01-01 · Tohoku J Exp Med · vol. 237 · número 3 · págs. 183–191
- Editorial
- Tohoku University
- Citado
- 20 citas · más que el 84% de estudios similares · 1.6× el promedio de su campo
- Referencias
- 55 trabajos
- Acceso
- Acceso abierto (publicación gratuita)
- Áreas de investigación
- Autoimmune and Inflammatory Disorders Research · Rheumatoid Arthritis Research and Therapies · Natural Compounds in Disease Treatment
- Palabras clave
- juvenile idiopathic arthritis, blueberry juice, etanercept, combination therapy, tumor necrosis factor inhibitors, interleukin-1, interleukin-1 receptor antagonist, anti-inflammatory activity, homeopathic remedies, ACR response criteria, adverse drug reactions
- MeSH
- humans, inflammation, rna, messenger, plant extracts, treatment outcome, phytotherapy, gene expression regulation, adolescent, female, male, arthritis, juvenile, etanercept, blueberry plants
6 autores
- Yingjie Zhong🇨🇳Jilin University
- Ye Wang🇨🇳Jilin University
- Jun Guo🇨🇳Jilin University
- Haifeng Chu🇨🇳Jilin University
- Yong Gao🇨🇳Jilin University
- Limin Pang🇨🇳Jilin University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Juvenile idiopathic arthritis (JIA) is the most common arthritis in the adolescents under the age of 16. Etanercept, an inhibitor of tumor necrosis factor, is often used to treat JIA despite its significant side effects. Homeopathic remedies, such as blueberries, have anti-inflammatory properties with fewer unwanted effects and should be considered as a primary treatment. We aimed to explore the efficacy and safety of combination therapy of blueberry and etanercept for JIA. Two hundred and one JIA patients were selected, and randomly and evenly assigned to three groups: ETA (50 mg of etanercept twice weekly), ETABJ (matched etanercept and 50 ml blueberry juice daily) and ETAPJ (matched etanercept and placebo juice). The severity of JIA was measured using American College of Rheumatology scales (ACR) 20, 50 and 70. The levels of pro-inflammatory cytokines, interleukin-1 (IL1) alpha and IL1 beta, and interleukin-1 receptor antagonist (IL1RA) were measured by qRT-PCR and ELISA. After a 6-month follow-up, the ACR20, ACR50 and ACR70 in an ETABJ group were higher than those in other two groups (P < 0.05), suggesting clinically meaningful improvement in JIA. Meanwhile, the symptoms and side effects were reduced significantly or absent in an ETABJ group, including mental diseases, retrobulbar optic neuritis, gaining weight, infection, cutaneous vasculitis, diarrhea, uveitis and pancytopenia. Blueberries reduced the levels of IL1 alpha and beta, and increased the level of IL1RA. Thus, a combination therapy of blueberry and etanercept can reduce the severity of JIA and should be developed as a new method for JIA therapy.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.